Proactive strategies include weekly blood pressure monitoring and angiotensin-converting enzyme (ACE) inhibitors for VEGFR inhibitor-induced hypertension, baseline electrocardiogram (ECGs) to manage QT prolongation induced by drugs such as crizotinib, and granulocyte colony-stimulating factor (G-CSF) for neutropenia in patients treated with CDK4/6 inhibitors. The gene discussed is CSF3; the disease is hypertensive disorder.